The global influenza vaccine market was valued at $5024.60 million in 2020, and is projected to reach $10,127.0 million by 2030, registering a CAGR of 7.20% from 2021 to 2030.
Contagious respiratory infections or illness due to influenza viruses is commonly termed as influenza. The four types of influenza viruses include Type A, Type B, Type C, and Type D. Amongst them, Type A and Type B are the most common types of influenza virus and are responsible for seasonal flu every year. Influenza A viruses are the only flu viruses known to cause flu infections, that is, the global flu epidemic. Epidemics can occur with the emergence of a new and highly contagious A virus that affects humans and has the potential to spread effectively among humans. Influenza C infection usually causes minor illnesses and is not thought to cause the flu pandemic. These viruses attack the respiratory system of an individual and are transmitted to other individuals by direct contact or inhalation of virus laden aerosols. Seasonal fever is characterized by a sudden onset of fever, cough, headache, muscle and joint pain, sore throat and runny nose. Coughing can be severe and can last for two weeks or more. The best identified way to prevent influenza is through vaccination, if neglected it could be life-threatening amongst high-risk groups. The burden of influenza can vary greatly and is determined by a number of factors including the circulatory system, the time of year, the effectiveness of a vaccine to prevent disease, and the number of people vaccinated.
Continuous mutations can cause annual flu epidemics due to high antigenetic variability of influenza viruses. For this reason, flu vaccines should be adapted to the current drift variation each year and used in vaccines to provide the highest possible protection. The WHO recommends doses for the development of an antigen vaccine prior to each flu season.
The key factors that drive the market growth include government initiatives worldwide to ensure well-being of population, minimal risk of side effects associated with influenza vaccines, technological advancements in existing vaccines, and development of new vaccines. In addition, funding and investments by companies in R&D activities supplement the growth of the market. However, longer timelines required for vaccine production and higher costs associated with the development hinder the growth of the market globally. On the contrary, routine immunization programs in the developed as well as developing countries provide newer opportunities for the growth of the influenza vaccine market.
The influenza vaccine market is segmented on the basis of vaccine type, technology, age group, route of administration, and region. By vaccine type, it is bifurcated into quadrivalent and trivalent. By technology, it is classified into egg-based and cell-based. By age group, it is divided into pediatric and adult. By route of administration, it is categorized into injection and nasal spray. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa.
North America accounted for the largest market share in 2020 and is expected to retain its dominance throughout the forecast period. This is attributed to the increased prevalence of influenza in the region, increase in government focus on immunization programs, emergence of new vaccines, and growth in technological advancements for vaccine administration. However, Middle East and Africa is expected to emerge as a lucrative area with maximum growth potential, due to the increase in awareness program, improvement in healthcare facilities, available disposable income, and rapid development of economic conditions.
Some of the key players operating in the influenza vaccine market are AstraZeneca plc., Biodiem, CSL Limited, Emergent BioSolutions, F. Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., GlaxoSmithKline plc, Merck & Co. Inc. (Merck Sharp & Dohme Corp.), Pfizer, Inc. and Sanofi Pasteur SA.
Contagious respiratory infections or illness due to influenza viruses is commonly termed as influenza. The four types of influenza viruses include Type A, Type B, Type C, and Type D. Amongst them, Type A and Type B are the most common types of influenza virus and are responsible for seasonal flu every year. Influenza A viruses are the only flu viruses known to cause flu infections, that is, the global flu epidemic. Epidemics can occur with the emergence of a new and highly contagious A virus that affects humans and has the potential to spread effectively among humans. Influenza C infection usually causes minor illnesses and is not thought to cause the flu pandemic. These viruses attack the respiratory system of an individual and are transmitted to other individuals by direct contact or inhalation of virus laden aerosols. Seasonal fever is characterized by a sudden onset of fever, cough, headache, muscle and joint pain, sore throat and runny nose. Coughing can be severe and can last for two weeks or more. The best identified way to prevent influenza is through vaccination, if neglected it could be life-threatening amongst high-risk groups. The burden of influenza can vary greatly and is determined by a number of factors including the circulatory system, the time of year, the effectiveness of a vaccine to prevent disease, and the number of people vaccinated.
Continuous mutations can cause annual flu epidemics due to high antigenetic variability of influenza viruses. For this reason, flu vaccines should be adapted to the current drift variation each year and used in vaccines to provide the highest possible protection. The WHO recommends doses for the development of an antigen vaccine prior to each flu season.
The key factors that drive the market growth include government initiatives worldwide to ensure well-being of population, minimal risk of side effects associated with influenza vaccines, technological advancements in existing vaccines, and development of new vaccines. In addition, funding and investments by companies in R&D activities supplement the growth of the market. However, longer timelines required for vaccine production and higher costs associated with the development hinder the growth of the market globally. On the contrary, routine immunization programs in the developed as well as developing countries provide newer opportunities for the growth of the influenza vaccine market.
The influenza vaccine market is segmented on the basis of vaccine type, technology, age group, route of administration, and region. By vaccine type, it is bifurcated into quadrivalent and trivalent. By technology, it is classified into egg-based and cell-based. By age group, it is divided into pediatric and adult. By route of administration, it is categorized into injection and nasal spray. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa.
North America accounted for the largest market share in 2020 and is expected to retain its dominance throughout the forecast period. This is attributed to the increased prevalence of influenza in the region, increase in government focus on immunization programs, emergence of new vaccines, and growth in technological advancements for vaccine administration. However, Middle East and Africa is expected to emerge as a lucrative area with maximum growth potential, due to the increase in awareness program, improvement in healthcare facilities, available disposable income, and rapid development of economic conditions.
Some of the key players operating in the influenza vaccine market are AstraZeneca plc., Biodiem, CSL Limited, Emergent BioSolutions, F. Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., GlaxoSmithKline plc, Merck & Co. Inc. (Merck Sharp & Dohme Corp.), Pfizer, Inc. and Sanofi Pasteur SA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global influenza vaccine market, with current trends and future estimations to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the market growth is provided. The market forecast is studied from 2021 to 2030.
- Quantitative analysis of the industry from 2020 to 2030 is presented to enable stakeholders to capitalize on prevailing market opportunities.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
BY VACCINE TYPE
- Quadrivalent
- Trivalent
BY TYPE
- Seasonal
- Pandemic
BY TECHNOLOGY
- Egg-based
- Cell-based
BY AGE GROUP
- Pediatric
- Adult
BY ROUTE OF ADMINISTRATION
- Injection
- Nasal Spray
BY REGION
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
List of Key Players Profiled in the Report
- Astrazeneca Plc (Astrazeneca)
- Biodiem
- Csl Limited (Seqirus GmbH)
- Emergent Biosolutions
- F. Hoffmann-La Roche Ltd.
- Gamma Vaccines Pty Ltd.
- Glaxosmithkline Plc
- Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
- Novartis Ag
- Pfizer, Inc.
- Sanofi
- Sinovac Biotech Ltd.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Executive summary Report description1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW3.1. Market definition and scope
3.2. Key findings
3.2.1. Top Player Positioning
3.2.2. Top investment pockets
3.2.3. Top winning strategies
3.3. Porter's five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. High prevalence of influenza
3.4.1.2. Increase in government focus on immunization programs
3.4.1.3. Emerging vaccines
3.4.1.4. Technological progress in vaccine administration
3.4.2. Restraints
3.4.2.1. Longer timelines and implementation of stringent regulations
3.4.2.2. High costs associated with the development of vaccines
3.4.3. Opportunity
3.4.3.1. High growth prospects in emerging markets
3.5. IMPACT ANALYSIS OF COVID-19 ON INFLUENZA VACCINE MARKET
CHAPTER 4: INFLUENZA VACCINE MARKET, BY VACCINE TYPE4.1. Overview
4.1.1. Market size and forecast
4.2. Quadrivalent
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Trivalent
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
CHAPTER 5: INFLUENZA VACCINE MARKET, BY TECHNOLOGY5.1. Overview
5.1.1. Market size and forecast
5.2. Egg-based
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Cell-based
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
CHAPTER 6: INFLUENZA VACCINE MARKET, BY AGE GROUP6.1. Overview
6.1.1. Market size and forecast
6.2. Pediatric
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Adult
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
CHAPTER 7: INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION7.1. Overview
7.1.1. Market size and forecast
7.2. Injection
7.2.1. Market size and forecast
7.2.2. Market analysis, by country
7.3. Nasal spray
7.3.1. Market size and forecast
7.3.2. Market analysis, by country
CHAPTER 8: GLOBAL INFLUENZA VACCINE MARKET, BY REGION8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends and opportunities
8.2.2. Market size and forecast, by vaccine type
8.2.3. Market size and forecast, by technology
8.2.4. Market size and forecast, by age group
8.2.5. Market size and forecast, by route of administration
8.2.6. Market size and forecast, by country
8.2.6.1. U.S. market size and forecast, by vaccine type
8.2.6.2. U.S. market size and forecast, by technology
8.2.6.3. U.S. market size and forecast, by age group
8.2.6.4. U.S. market size and forecast, by route of administration
8.2.6.5. Canada market size and forecast, by vaccine type
8.2.6.6. Canada market size and forecast, by technology
8.2.6.7. Canada market size and forecast, by age group
8.2.6.8. Canada market size and forecast, by route of administration
8.2.6.9. Mexico market size and forecast, by vaccine type
8.2.6.10. Mexico market size and forecast, by technology
8.2.6.11. Mexico market size and forecast, by age group
8.2.6.12. Mexico market size and forecast, by route of administration
8.3. Europe
8.3.1. Key market trends and opportunities
8.3.2. Market size and forecast, by vaccine type
8.3.3. Market size and forecast, by technology
8.3.4. Market size and forecast, by age group
8.3.5. Market size and forecast, by route of administration
8.3.6. Market size and forecast, by country
8.3.6.1. Germany market size and forecast, by vaccine type
8.3.6.2. Germany market size and forecast, by technology
8.3.6.3. Germany market size and forecast, by age group
8.3.6.4. Germany market size and forecast, by route of administration
8.3.6.5. France market size and forecast, by vaccine type
8.3.6.6. France market size and forecast, by technology
8.3.6.7. France market size and forecast, by age group
8.3.6.8. France market size and forecast, by route of administration
8.3.6.9. UK market size and forecast, by vaccine type
8.3.6.10. UK market size and forecast, by technology
8.3.6.11. UK market size and forecast, by age group
8.3.6.12. UK market size and forecast, by route of administration
8.3.6.13. Italy market size and forecast, by vaccine type
8.3.6.14. Italy market size and forecast, by technology
8.3.6.15. Italy market size and forecast, by age group
8.3.6.16. Italy market size and forecast, by route of administration
8.3.6.17. Spain market size and forecast, by vaccine type
8.3.6.18. Spain market size and forecast, by technology
8.3.6.19. Spain market size and forecast, by age group
8.3.6.20. Spain market size and forecast, by route of administration
8.3.6.21. Rest of Europe market size and forecast, by vaccine type
8.3.6.22. Rest of Europe market size and forecast, by technology
8.3.6.23. Rest of Europe market size and forecast, by age group
8.3.6.24. Rest of Europe market size and forecast, by route of administration
8.4. Asia-Pacific
8.4.1. Key market trends and opportunities
8.4.2. Market size and forecast, by vaccine type
8.4.3. Market size and forecast, by technology
8.4.4. Market size and forecast, by age group
8.4.5. Market size and forecast, by route of administration
8.4.5.1. Japan market size and forecast, by vaccine type
8.4.5.2. Japan market size and forecast, by technology
8.4.5.3. Japan market size and forecast, by age group
8.4.5.4. Japan market size and forecast, by route of administration
8.4.5.5. China market size and forecast, by vaccine type
8.4.5.6. China market size and forecast, by technology
8.4.5.7. China market size and forecast, by age group
8.4.5.8. China market size and forecast, by route of administration
8.4.5.9. India market size and forecast, by vaccine type
8.4.5.10. India market size and forecast, by technology
8.4.5.11. India market size and forecast, by age group
8.4.5.12. India market size and forecast, by route of administration
8.4.5.13. Australia market size and forecast, by vaccine type
8.4.5.14. Australia market size and forecast, by technology
8.4.5.15. Australia market size and forecast, by age group
8.4.5.16. Australia market size and forecast, by route of administration
8.4.5.17. South Korea market size and forecast, by vaccine type
8.4.5.18. South Korea market size and forecast, by technology
8.4.5.19. South Korea market size and forecast, by age group
8.4.5.20. South Korea market size and forecast, by route of administration
8.4.5.21. Rest of Asia-Pacific market size and forecast, by vaccine type
8.4.5.22. Rest of Asia-Pacific market size and forecast, by technology
8.4.5.23. Rest of Asia-Pacific market size and forecast, by age group
8.4.5.24. Rest of Asia-Pacific market size and forecast, by route of administration
8.5. Latin America
8.5.1. Key market trends and opportunities
8.5.2. Market size and forecast, by vaccine type
8.5.3. Market size and forecast, by technology
8.5.4. Market size and forecast, by age group
8.5.5. Market size and forecast, by route of administration
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil market size and forecast, by vaccine type
8.5.6.2. Brazil market size and forecast, by technology
8.5.6.3. Brazil market size and forecast, by age group
8.5.6.4. Brazil market size and forecast, by route of administration
8.5.6.5. Saudi Arabia market size and forecast, by vaccine type
8.5.6.6. Saudi Arabia market size and forecast, by technology
8.5.6.7. Saudi Arabia market size and forecast, by age group
8.5.6.8. Saudi Arabia market size and forecast, by route of administration
8.5.6.9. South Africa market size and forecast, by vaccine type
8.5.6.10. South Africa market size and forecast, by technology
8.5.6.11. South Africa market size and forecast, by age group
8.5.6.12. South Africa market size and forecast, by route of administration
8.5.6.13. Rest of LAMEA market size and forecast, by vaccine type
8.5.6.14. Rest of LAMEA market size and forecast, by technology
8.5.6.15. Rest of LAMEA market size and forecast, by age group
8.5.6.16. Rest of LAMEA market size and forecast, by route of administration
CHAPTER 9: COMPANY PROFILES9.1. ASTRAZENECA PLC (ASTRAZENECA)
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.2. BIODIEM LTD
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
Biodiem ltd. offers the following influenza vaccine:
9.2.5. Business performance
9.2.6. Key strategic moves and developments
9.3. CSL LIMITED (SEQIRUS GMBH)
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments
9.4. EMERGENT BIOSOLUTIONS INC.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
Emergent biosolutions inc. offers following influenza vaccines:
9.4.5. Business performance
9.4.6. Key strategic moves and developments
9.5. F. HOFFMANN-LA ROCHE LTD.
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.6. GAMMA VACCINES PTY LTD.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.7. GLAXOSMITHKLINE PLC
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.7.6. Key strategic moves and developments
9.8. MERCK & CO., INC. (MERCK SHARP & DOHME CORP.)
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.9. PFIZER, INC.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments
9.10. SANOFI
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
9.10.6. Key strategic moves and developments
List of Tables
TABLE 01. GLOBAL INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 02. INFLUENZA VACCINE MARKET FOR QUADRIVALENT, BY REGION, 2018-2026, ($MILLION)
TABLE 03. INFLUENZA VACCINE MARKET FOR TRIVALENT, BY REGION, 2020-2030, ($MILLION)
TABLE 04. GLOBAL INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 05. EGG-BASED INFLUENZA VACCINE MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 06. CELL-BASED INFLUENZA VACCINE MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 07. GLOBAL INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 08. INFLUENZA VACCINE MARKET FOR PEDIATRIC AGE GROUP, BY REGION, 2020-2030, ($MILLION)
TABLE 09. INFLUENZA VACCINE MARKET FOR ADULT AGE GROUP, BY REGION, 2020-2030, ($MILLION)
TABLE 10. GLOBAL INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 11. INFLUENZA VACCINE MARKET FOR INJECTION, BY REGION, 2020-2030, ($MILLION)
TABLE 12. INFLUENZA VACCINE MARKET FOR NASAL SPRAY, BY REGION, 2020-2030, ($MILLION)
TABLE 13. GLOBAL INFLUENZA VACCINE MARKET, BY REGION, 2020-2030, ($MILLION)
TABLE 14. NORTH AMERICA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 15. NORTH AMERICA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 16. NORTH AMERICA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 17. NORTH AMERICA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 18. NORTH AMERICA INFLUENZA VACCINE MARKET, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 19. U.S. INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 20. U.S. INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 21. U.S. INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 22. U.S. INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 23. CANADA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 24. CANADA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 25. CANADA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 26. CANADA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 27. MEXICO INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 28. MEXICO INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 29. MEXICO INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 30. MEXICO INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 31. EUROPE INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 32. EUROPE INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 33. EUROPE INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 34. EUROPE INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 35. EUROPE INFLUENZA VACCINE MARKET, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 36. GERMANY INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 37. GERMANY INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 38. GERMANY INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 39. GERMANY INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 40. FRANCE INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 41. FRANCE INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 42. FRANCE INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 43. FRANCE INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 44. UK INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 45. UK INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 46. UK INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 47. UK INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 48. ITALY INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 49. ITALY INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 50. ITALY INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 51. ITALY INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 52. SPAIN INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 53. SPAIN INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 54. SPAIN INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 55. SPAIN INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 56. REST OF EUROPE INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 57. REST OF EUROPE INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 58. REST OF EUROPE INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 59. REST OF EUROPE INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 60. ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 61. ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 62. ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 63. ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 64. JAPAN INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 65. JAPAN INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 66. JAPAN INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 67. JAPAN INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 68. CHINA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 69. CHINA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 70. CHINA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 71. CHINA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 72. INDIA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 73. INDIA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 74. INDIA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 75. INDIA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 76. AUSTRALIA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 77. AUSTRALIA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 78. AUSTRALIA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 79. AUSTRALIA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 80. SOUTH KOREA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 81. SOUTH KOREA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 82. SOUTH KOREA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 83. SOUTH KOREA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 88. LAMEA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 89. LAMEA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 90. LAMEA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 91. LAMEA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 92. LAMEA INFLUENZA VACCINE MARKET, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 93. BRAZIL INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 94. BRAZIL INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 95. BRAZIL INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 96. BRAZIL INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 97. SAUDI ARABIA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 98. SAUDI ARABIA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 99. SAUDI ARABIA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 100. SAUDI ARABIA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 101. SOUTH AFRICA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 102. SOUTH AFRICA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 103. SOUTH AFRICA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 104. SOUTH AFRICA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 105. REST OF LAMEA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020-2030, ($MILLION)
TABLE 106. REST OF LAMEA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020-2030, ($MILLION)
TABLE 107. REST OF MIDDLE EAST AND AFRICA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 108. REST OF LAMEA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 109. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 110. ASTRAZENECA: OPERATING SEGMENTS
TABLE 111. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 112. BIODIEM LTD: COMPANY SNAPSHOT
TABLE 113. BIODIEM: OPERATING SEGMENTS
TABLE 114. BIODIEM LTD: PRODUCT PORTFOLIO
TABLE 115. CSL LIMITED: COMPANY SNAPSHOT
TABLE 116. CSL LIMITED: OPERATING SEGMENTS
TABLE 117. CSL LIMITED: PRODUCT PORTFOLIO
TABLE 118. EMERGENT BIOSOLUTIONS INC: COMPANY SNAPSHOT
TABLE 119. EMERGENT BIOSOLUTIONS INC: PRODUCT PORTFOLIO
TABLE 120. ROCHE: COMPANY SNAPSHOT
TABLE 121. ROCHE: OPERATING SEGMENTS
TABLE 122. ROCHE: PRODUCT PORTFOLIO
TABLE 123. GAMMA VACCINES: COMPANY SNAPSHOT
TABLE 124. GAMMA VACCINES: OPERATING SEGMENTS
TABLE 125. GAMMA VACCINES: PRODUCT TYPE PORTFOLIO
TABLE 126. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 127. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 128. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 129. MERCK.: COMPANY SNAPSHOT
TABLE 130. MERCK: OPERATING SEGMENTS
TABLE 131. MERCK: PRODUCT TYPE PORTFOLIO
TABLE 132. PFIZER INC: COMPANY SNAPSHOT
TABLE 133. PFIZER INC: PRODUCT TYPE PORTFOLIO
TABLE 134. SANOFI: COMPANY SNAPSHOT
TABLE 135. SANOFI: OPERATING SEGMENTS
TABLE 136. SANOFI: PRODUCT TYPE PORTFOLIO
List of Figures
FIGURE 01. INFLUENZA VACCINE MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. TOP WINNING STRATEGIES, BY YEAR, 2018-2020*
FIGURE 05. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020* (%)
FIGURE 06. TOP WINNING STRATEGIES, BY COMPANY, 2018-2020*
FIGURE 07. LOW-MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08. HIGH BARGAINING POWER OF BUYERS
FIGURE 09. MODERATE THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE THREAT OF SUBSTITUTION
FIGURE 11. HIGH INTENSITY OF COMPETITIVE RIVALRY
FIGURE 12. TOP IMPACTING FACTORS
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE MARKET FOR QUADRIVALENT, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE MARKET FOR TRIVALENT, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF EGG-BASED INFLUENZA VACCINE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CELL CULTURE INFLUENZA VACCINE MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE FOR PEDIATRIC AGE GROUP, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE MARKET FOR ADULT AGE GROUP, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE FOR INJECTION, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE MARKET FOR NASAL SPRAY, BY COUNTRY, 2020 & 2030 (%)
FIGURE 21. ASTRAZENECA: REVENUE, 2018-2020 ($MILLION)
FIGURE 22. ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23. ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 24. BIODIEM LTD: REVENUE, 2018-2020 ($MILLION)
FIGURE 25. CSL LIMITED: REVENUE, 2018-2020 ($MILLION)
FIGURE 26. CSL LIMITED: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27. CSL LIMITED: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 28. EMERGENT BIOSOLUTIONS INC: REVENUE, 2018-2020 ($MILLION)
FIGURE 29. EMERGENT BIOSOLUTIONS INC: REVENUE SHARE BY PRODUCT, 2020 (%)
FIGURE 30. EMERGENT BIOSOLUTIONS INC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 31. ROCHE: REVENUE, 2018-2020 ($MILLION)
FIGURE 32. ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 33. ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 34. GLAXOSMITHKLINE PLC: REVENUE, 2018-2020 ($MILLION)
FIGURE 35. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 37. MERCK: REVENUE, 2018-2020 ($MILLION)
FIGURE 38. MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39. MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 40. PFIZER INC: REVENUE, 2018-2020 ($MILLION)
FIGURE 41. PFIZER INC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42. SANOFI: REVENUE, 2018-2020 ($MILLION)
FIGURE 43. SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44. SANOFI: REVENUE SHARE BY REGION, 2020 (%)
Companies Mentioned
- AstraZeneca plc.
- Biodiem
- CSL Limited
- Emergent BioSolutions
- F. Hoffmann-La Roche Ltd.
- Gamma Vaccines Pty Ltd.
- GlaxoSmithKline plc
- Merck & Co. Inc. (Merck Sharp & Dohme Corp.)
- Novartis AG
- Pfizer Inc.
- Sanofi Pasteur SA
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 217 |
| Published | August 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 5024.6 million |
| Forecasted Market Value ( USD | $ 10127 million |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
